Rubén D Artero Allepuz

Title: Innovations by Rubén D Artero Allepuz

Introduction

Rubén D Artero Allepuz is a notable inventor based in Valencia, Spain. He has made significant contributions to the field of medical research, particularly in the treatment of myotonic dystrophy type 1. His innovative approach focuses on the modulation of microRNAs, which play a crucial role in gene expression.

Latest Patents

Rubén D Artero Allepuz holds a patent titled "Modulation of microRNAs against myotonic dystrophy type 1 and antagonists of microRNAs therefor." This invention provides the use of inhibitors of microRNAs that repress the MBNL1 and/or MBNL2 genes for the manufacture of a medicinal product aimed at treating myotonic dystrophy type 1. By inhibiting these microRNAs, the endogenous levels of the corresponding proteins MBNL1 and/or MBNL2 can be increased, thereby alleviating symptoms of the disease. The invention particularly emphasizes the inhibition of microRNAs miR-23b-3p and miR-218-5p, which are expressed in the main affected organs, including skeletal muscle, heart, and the central nervous system. Additionally, the patent provides oligoribonucleotide or oligoribonucleotide analogue antagonists, preferably antagomiRs, that are chemically modified to enhance their interaction with the target, stability in vivo, and ability to penetrate cells and distribute throughout tissues and organs.

Career Highlights

Throughout his career, Rubén D Artero Allepuz has worked with esteemed institutions such as the Universitat De Valencia and Aum Lifetech, Inc. His work has been instrumental in advancing the understanding and treatment of myotonic dystrophy type 1.

Collaborations

Rubén has collaborated with notable individuals in his field, including María Beatriz Llamusí Troisi and Estefanía Cerro Herreros. Their combined efforts have contributed to the development of innovative solutions in medical research.

Conclusion

Rubén D Artero Allepuz is a pioneering inventor whose work in the modulation of microRNAs has the potential to transform the treatment of myotonic dystrophy type 1. His contributions to medical research highlight the importance of innovation in addressing complex health challenges.